 KalVista Pharmaceuticals Inc. shares KALV, -1.86 tumbled 26 in premarket trade Tuesday, after the company said its halting a Phase 2 trial of a treatment for hereditary angioedema, after multiple patients showed liver enzyme elevations. No patients had concomitant elevation of bilirubin levels and all were asymptomatic, the company said in a statement. 